@article{aa2ce10cd34a40bda09a6edb1a2f2062,
title = "Ability of herpes simplex virus vectors to boost immune responses to DNA vectors and to protect against challenge by simian immunodeficiency virus",
abstract = "The immunogenicity and protective capacity of replication-defective herpes simplex virus (HSV) vector-based vaccines were examined in rhesus macaques. Three macaques were inoculated with recombinant HSV vectors expressing Gag, Env, and a Tat-Rev-Nef fusion protein of simian immunodeficiency virus (SIV). Three other macaques were primed with recombinant DNA vectors expressing Gag, Env, and a Pol-Tat-Nef-Vif fusion protein prior to boosting with the HSV vectors. Robust anti-Gag and anti-Env cellular responses were detected in all six macaques. Following intravenous challenge with wild-type, cloned SIV239, peak and 12-week plasma viremia levels were significantly lower in vaccinated compared to control macaques. Plasma SIV RNA in vaccinated macaques was inversely correlated with anti-Rev ELISPOT responses on the day of challenge (P value < 0.05), anti-Tat ELISPOT responses at 2 weeks post challenge (P value < 0.05) and peak neutralizing antibody titers pre-challenge (P value 0.06). These findings support continued study of recombinant herpesviruses as a vaccine approach for AIDS.",
keywords = "AIDS vaccine, DNA prime, Recombinant HSV vectors, Rhesus macaque, SIV",
author = "Amitinder Kaur and Sanford, {Hannah B.} and Deirdre Garry and Sabine Lang and Klumpp, {Sherry A.} and Daisuke Watanabe and Bronson, {Roderick T.} and Lifson, {Jeffrey D.} and Margherita Rosati and Pavlakis, {George N.} and Felber, {Barbara K.} and Knipe, {David M.} and Desrosiers, {Ronald C.}",
note = "Funding Information: This study was supported by HIV Vaccine Research and Development grant AI46006 from the NIAID, PHS grant RR00168 and with federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. NO1-CO-12400. The authors thank the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH for providing SIV239 p55 antigen and the 183-H12-5C mAb to HIV-1 p24, Dr. K Kent and Ms C. Arnold and the NIBSC Centralised Facility for AIDS Reagents supported by EU programme EVA contract and the UK Medical Research Council for the KK75 mAb to SIV Nef, P. Roth for DNA preparation, M. Piatak Jr. and K. Oswald for assistance with plasma viral load measurements, Keith Mansfield, Angela Carville and the staff of the Division of Primate Medicine at NEPRC for assistance with animal studies, David Watkins for providing viral load data on control SIV239-infected rhesus macaques and Neal DeLuca for providing the HSV d106 vector. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services nor does mention of trade names, commercial products or organization imply endorsement by the U.S. Government.",
year = "2007",
month = jan,
day = "20",
doi = "10.1016/j.virol.2006.08.007",
language = "English (US)",
volume = "357",
pages = "199--214",
journal = "Virology",
issn = "0042-6822",
publisher = "Academic Press Inc.",
number = "2",
}
